Elucidating mechanisms for artemisinin-induced dormancy in Plasmodium falciparum

阐明青蒿素诱导恶性疟原虫休眠的机制

基本信息

  • 批准号:
    10742385
  • 负责人:
  • 金额:
    $ 22.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-16 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

Project Summary Among the numerous problems plaguing the malaria elimination efforts is the emergence and spread of drug resistance in P. falciparum. Resistance to artemisinin has led to reduced efficacy of artemisinin combination therapy (ACTs) and ultimately selection of resistance to the partner drugs (e.g., piperaquine). Clearly the threat of multi-drug resistant malaria is as important today as it has ever been, with the precious gains in malaria control threatened by the potential for the spread of P. falciparum strains that are resistant to all currently available treatment drugs. Resistance to artemisinin is not the only factor responsible for treatment failures. Even before artemisinin resistance emerged, recrudescent infections were commonly observed when patients were treated with artemisinin derivatives alone. In some studies, even 5-7 days of treatment with artesunate alone led to ~10% recrudescent infections. The underlying cause of these recrudescent infections has been attributed to the unique ability of artemisinin to arrest the growth of ring stages of P. falciparum. These dormant rings can persist for days to weeks before recovering and growing normally to cause a recrudescent infection. Our published and preliminary data led us to the hypothesis that selection of artemisinin resistance is a two-step process in which the initial responses of the parasite to artemisinin drug pressure is an enhanced dormancy phenotype that confers increased tolerance to drug; subsequently resistance conferring mutations occur (e.g., K13). In Aim 1 we will overexpress genes in a novel chromosome 10 copy number variant we identified in independently derived artemisinin-resistant clones. In Aim 2 will use novel high content imaging assays to quantify enhanced dormancy recovery phenotypes in artemisinin-resistant versus -susceptible P. falciparum. The results of these studies will provide evidence for the molecular basis of recovery from artemisinin-induced dormancy and possibly reveal new mechanisms of resistance to artemisinin.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DENNIS E KYLE其他文献

DENNIS E KYLE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DENNIS E KYLE', 18)}}的其他基金

Lead optimization and target identification of drugs targeting hypnozoites
催眠药物的先导化合物优化和靶点识别
  • 批准号:
    10035076
  • 财政年份:
    2020
  • 资助金额:
    $ 22.65万
  • 项目类别:
Lead optimization and target identification of drugs targeting hypnozoites
催眠药物的先导化合物优化和靶点识别
  • 批准号:
    10455026
  • 财政年份:
    2020
  • 资助金额:
    $ 22.65万
  • 项目类别:
Lead optimization and target identification of drugs targeting hypnozoites
催眠药物的先导化合物优化和靶点识别
  • 批准号:
    10688200
  • 财政年份:
    2020
  • 资助金额:
    $ 22.65万
  • 项目类别:
Lead optimization and target identification of drugs targeting hypnozoites
催眠药物的先导化合物优化和靶点识别
  • 批准号:
    10231087
  • 财政年份:
    2020
  • 资助金额:
    $ 22.65万
  • 项目类别:
Combining Liver Stage Culture System with Backcross Genetics to Discover Antimalarial Drug Resistance Loci
肝阶段培养系统与回交遗传学相结合发现抗疟药物耐药位点
  • 批准号:
    9891003
  • 财政年份:
    2019
  • 资助金额:
    $ 22.65万
  • 项目类别:
Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity
具有多阶段抗疟活性的口服生物可利用 4(1H)-喹诺酮类药物
  • 批准号:
    10598072
  • 财政年份:
    2019
  • 资助金额:
    $ 22.65万
  • 项目类别:
Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity
具有多阶段抗疟活性的口服生物可利用 4(1H)-喹诺酮类药物
  • 批准号:
    9913468
  • 财政年份:
    2019
  • 资助金额:
    $ 22.65万
  • 项目类别:
Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity
具有多阶段抗疟活性的口服生物可利用 4(1H)-喹诺酮类药物
  • 批准号:
    10373024
  • 财政年份:
    2019
  • 资助金额:
    $ 22.65万
  • 项目类别:
Lead Optimization of Bis-benzimidazole Analogs for Pathogenic Free-living Amoebae
双苯并咪唑类似物针对致病性自由生活阿米巴原虫的先导化合物优化
  • 批准号:
    9090018
  • 财政年份:
    2015
  • 资助金额:
    $ 22.65万
  • 项目类别:
Extreme Resistance to Mitochondrial Inhibitors in Plasmodium falciparum
恶性疟原虫对线粒体抑制剂的极度耐药性
  • 批准号:
    8624359
  • 财政年份:
    2014
  • 资助金额:
    $ 22.65万
  • 项目类别:

相似海外基金

Variation in Resistance and Fitness to Artemisinins in African Malaria
非洲疟疾对青蒿素的耐药性和适应性的变化
  • 批准号:
    9010406
  • 财政年份:
    2015
  • 资助金额:
    $ 22.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了